A short burst of reward curbs the addictiveness of ketamine

Campbell, Rianne; Lobo, Mary Kay

doi:10.1038/d41586-022-01948-w

NEWS AND VIEWS
27 July 2022

A short burst of reward curbs the addictiveness of ketamine

An analysis of ketamine and cocaine use in mice reveals that the drugs trigger release of the neurotransmitter dopamine through different mechanisms, and indicates that the risk of addiction to ketamine is low.

Rianne Campbell⁰ &
Mary Kay Lobo¹

Rianne Campbell
1. Rianne Campbell is in the Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA.
View author publications

You can also search for this author in PubMed Google Scholar
Mary Kay Lobo
1. Mary Kay Lobo is in the Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA.
View author publications

You can also search for this author in PubMed Google Scholar

Access through your institution

Buy or subscribe

Ketamine is increasingly being used as a fast-acting antidepressant in research and in certain clinical settings¹. But there are concerns around its therapeutic use, because it is classified as having low to moderate potential for physical or psychological dependence². Substances are considered addictive if they lead to compulsive use despite negative consequences. Writing in Nature, Simmler et al.³ investigate whether ketamine causes the behavioural and neuronal changes typically seen with highly addictive substances. They report that ketamine fails to establish key addiction-like behaviours in mice, and does not produce changes in the brain’s reward system that are linked to drug craving.

Access options

Access through your institution

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Nature 608, 271-272 (2022)

doi: https://doi.org/10.1038/d41586-022-01948-w

References

Krystal, J. H., Abdallah, C. G., Sanacora, G., Charney, D. S. & Duman, R. S. Neuron 101, 774–778 (2019).
Article PubMed Google Scholar
Morgan, C. J. A., Curran, H. V. & the Independent Scientific Committee on Drugs (ISCD). Addiction 107, 27–38 (2012).
Article PubMed Google Scholar
Simmler, L. D. et al. Nature 608, 368–373 (2022).
Article Google Scholar
Dayan, P. & Niv, Y. Curr. Opin. Neurobiol. 18, 185–196 (2008).
Article PubMed Google Scholar
Saunders, B. T., Richard, J. M., Margolis, E. B. & Janak, P. H. Nature Neurosci. 21, 1072–1083 (2018).
Article PubMed Google Scholar
Autry, A. E. et al. Nature 475, 91–95 (2011).
Article PubMed Google Scholar
Ford, C. P. Neuroscience 282, 13–22 (2014).
Article PubMed Google Scholar
Mameli, M. et al. Nature Neurosci. 12, 1036–1041 (2009).
Article PubMed Google Scholar
Pascoli, V. et al. Nature 509, 459–464 (2014).
Article PubMed Google Scholar
Venniro, M., Banks, M. L., Heilig, M., Epstein, D. H. & Shaham, Y. Nature Rev. Neurosci. 21, 625–643 (2020).
Article PubMed Google Scholar
De Luca, M. T. & Badiani, A. Psychopharmacology 214, 549–556 (2011).
Article PubMed Google Scholar
Berman, R. M. et al. Biol. Psychiatry 47, 351–354 (2000).
Article PubMed Google Scholar
Graziane, N. M. et al. Nature Neurosci. 19, 915–925 (2016).
Article PubMed Google Scholar
Kruyer, A., Kalivas, P. W. & Scofield, M. D. Neuropsychopharmacology https://doi.org/10.1038/s41386-022-01338-w (2022).
Article Google Scholar
Price, R. B. & Duman, R. Mol. Psychiatry 25, 530–543 (2020).
Article PubMed Google Scholar
Kalivas, P. W. & Volkow, N. D. Am. J. Psychiatry 162, 1403–1413 (2005).
Article PubMed Google Scholar